Who Owns FibroGen Company?

FibroGen Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls FibroGen?

Delving into the ownership structure of a company is like unlocking its strategic DNA. Recent developments, such as AstraZeneca's acquisition of FibroGen's China unit, highlight the importance of understanding who calls the shots. FibroGen, a pioneer in biopharmaceutical innovation since 1993, is a publicly traded company with a complex ownership landscape.

Currently, with a market capitalization of approximately $31.7 million, understanding FibroGen SWOT Analysis is crucial to understanding the company's potential. This analysis will dissect the ownership dynamics of FibroGen (NASDAQ: FGEN), from its founders and early investors to its current mix of institutional, insider, and retail shareholders. This exploration is vital for anyone looking to understand the company's governance, financial performance, and future, especially considering the influence of FibroGen executives and FibroGen investors.

The story of FibroGen began in 1993 in San Francisco, California. The company was founded by Thomas B. Neff and Rory Riggs. This marked the start of a biopharmaceutical journey focused on innovative treatments.

Thomas B. Neff served as the CEO and Chairman, guiding the company for many years. Rory Riggs, a co-founder, also had experience founding other companies, adding to the early leadership's breadth. The initial funding was crucial, setting the stage for future developments.

FibroGen secured its initial capital through seed funding. Venture capital firms, including Kleiner Perkins Caufield & Byers and Institutional Venture Partners, provided the initial investment of $12 million. This early financial backing was vital for launching the company's research and development efforts.

Founders

Thomas B. Neff and Rory Riggs founded FibroGen.

Initial Funding

Seed funding of $12 million from venture capital firms.

Early Focus

Emphasis on Hypoxia-Inducible Factor (HIF) biology.

Key Drug

Development of Roxadustat for anemia patients.

Strategic Partnerships

Collaborations with AstraZeneca and Astellas.

Leadership Transition

James Schoeneck named interim CEO after Thomas Neff's passing in August 2019.

The early structure involved venture capital firms as major . The focus on HIF biology led to the development of Roxadustat, a key drug. Strategic partnerships with companies like AstraZeneca and Astellas provided significant financial support and expanded the drug's reach. Thomas Neff's leadership was critical for 25 years. After his passing in 2019, James Schoeneck became interim CEO. As of 2024, understanding the initial ownership provides insight into the company's early strategic decisions and financial backing.

Key Takeaways

Understanding the founders and early investors provides a foundation for analyzing and its future. The initial funding and strategic partnerships were critical for the company's early growth.

• Thomas B. Neff and Rory Riggs were the founders.
• Initial funding of $12 million from venture capital.
• Focus on HIF biology and Roxadustat.
• Partnerships with AstraZeneca and Astellas.

FibroGen SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of FibroGen's ownership structure has been marked by significant transitions since its initial public offering (IPO) on November 14, 2014. The IPO, which listed the company on the NASDAQ Global Select Market under the ticker symbol FGEN, established an initial market capitalization of $1.02 billion. This event set the stage for a dynamic ownership landscape, shaped by institutional investors, insider holdings, and retail participation. Understanding the shifts in ownership is crucial for assessing the company's strategic direction and financial health.

The company's ownership has been influenced by strategic partnerships and transactions. For instance, collaborations with AstraZeneca and Astellas have been pivotal in funding and expanding the global reach of products like Roxadustat. The planned sale of FibroGen China to AstraZeneca, expected to finalize by mid-2025 for approximately $185 million, is set to simplify the company's capital structure and extend its cash runway, projecting into the second half of 2027. These strategic moves reflect how ownership changes can directly impact FibroGen's operational and financial strategies.

As of June 5, 2025, FibroGen has a significant institutional presence, with 83 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC. These institutional investors collectively hold a substantial portion of the company's shares, totaling 33,950,400 shares, which represents approximately 33.60% of the institutional shares. Key institutional investors include Armistice Capital, LLC, Vanguard Group Inc., Acadian Asset Management LLC, and Primecap Management Co./CA/. The strategic influence of these major shareholders, along with the company's executive team, is a key element in understanding the company's trajectory. For more information on the company's target market, consider reading this article: Target Market of FibroGen.

Ownership Insights

FibroGen's ownership structure is a mix of institutional, insider, and retail investors.

• Institutional investors hold a significant portion of the shares.
• Strategic partnerships have been crucial for funding and global reach.
• The sale of FibroGen China is set to impact the company's financial structure.
• Insider ownership also plays a role in the company's direction.

FibroGen PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of June 2025, the FibroGen Board of Directors includes James Schoeneck as the Independent Chairman, Jeffrey Edwards as an Independent Director, Michael Kauffman as a Director, Maykin Ho as an Independent Director, and Aoife Brennan as an Independent Director. Thane Wettig, the Chief Executive Officer, also serves on the board. The average tenure of the board members is approximately 5.7 years, indicating a relatively experienced group guiding the company. This composition reflects the current FibroGen leadership team.

The board has seen some recent changes. In September 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema resigned, leading to adjustments in committee assignments. These changes in FibroGen's board of directors, while not due to any disagreements with company policies, highlight the ongoing evolution of the company's governance structure. For more information, you can read Revenue Streams & Business Model of FibroGen.

Regarding voting rights, each share of FibroGen Common Stock generally carries one vote. Shareholders of Common Stock are entitled to vote on all matters presented for a stockholder vote. Preferred Shares typically have voting rights only in specific situations as outlined in the Articles of Association, such as during merger transactions or directed share issues. The company amended its bylaws in April 2025, modifying quorum requirements for stockholder meetings, changing it from a majority to at least one-third of outstanding shares entitled to vote. Similarly, for matters requiring a separate class vote, the quorum was adjusted to at least one-third of the voting power of that class. These adjustments are part of the ongoing corporate governance of FibroGen.

Key Takeaways on FibroGen's Governance

FibroGen's board includes experienced members with an average tenure of over 5 years.

• Shareholders have voting rights, with quorum requirements recently updated.
• Changes in board composition reflect ongoing adjustments in corporate governance.
• The company's bylaws were amended in April 2025.
• The annual meeting of stockholders was held on June 4, 2025.

FibroGen Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, FibroGen has experienced significant shifts in its ownership and strategic direction. A key development was the February 2025 announcement of the sale of FibroGen China to AstraZeneca. This transaction, initially valued at approximately $160 million and later updated to $185 million in May 2025, is expected to conclude by the third quarter of 2025. This move is projected to extend FibroGen's financial runway into the second half of 2027.

In terms of leadership, Thane Wettig was appointed as Chief Executive Officer in October 2023. However, there have been executive departures as part of cost reduction efforts. These included the Chief Financial Officer Juan Graham and Chief Medical Officer Deyaa Adib, M.D., in late 2024. These changes reflect the company's efforts to streamline operations and focus on core development programs.

Ownership trends indicate a dynamic institutional landscape for FibroGen. As of June 2025, the company has 83 institutional owners. While some investors increased their positions in Q1 2025, a larger number decreased their holdings. Major institutional holders include Armistice Capital, LLC, Vanguard Group Inc., and BlackRock, Inc. The company's stock price has seen a significant decline, with a 74.36% decrease between June 2024 and June 2025, alongside a 26% drop in the month leading up to April 2025. To address this, a reverse stock split of 1-for-25 was implemented on June 16, 2025.

Key Developments

Sale of FibroGen China to AstraZeneca for approximately $185 million, expected to close Q3 2025.

Appointment of Thane Wettig as CEO in October 2023.

Executive departures as part of cost reduction efforts in late 2024.

Ownership Trends

83 institutional owners as of June 2025.

Significant stock price decline of 74.36% between June 2024 and June 2025.

Reverse stock split of 1-for-25 effective June 16, 2025.

FibroGen Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs